|
- 积分
- 56
- 威望
- 56
- 包包
- 422
|
本帖最后由 细胞海洋 于 2013-5-6 09:46 编辑
+ X a6 Y- R+ ~' m! K6 ^+ L# M. D
1 l( ]. w @3 L9 S0 G0 x FThe Delivery of Regenerative Medicines and Their Impact on Healthcare
5 F; A6 M9 i3 o7 {' P% WEdited by
& |# r- b( s. f9 X( i2 x% i% WDr. Catherine D. Prescott, f d- G4 N1 \ B9 m6 c" P. k
Professor Dame Julia Polak* }2 P1 ~: F# K8 W0 ]9 {% K
) \$ O; D7 ~+ q2 p9 Z$ fContents% n# {. Z; f! A7 v
Foreword...................................................................................................................vii
" }4 q' n8 z) o/ BPreface.......................................................................................................................ix9 R4 x7 w4 M' B# P3 |* D
Acknowledgments......................................................................................................xi j8 A& H! J7 ~& M b+ B
About the Editors.................................................................................................... xiii, y4 ^; R3 i+ {0 S5 [8 \
Contributors..............................................................................................................xv
: a3 [" J, K' h/ A- I. OSection 1 I ntroduction
9 {9 k# J& j' y! D- X7 ^Chapter 1 What Is Regenerative Medicine?...........................................................3
9 c U- N: ?4 R) KJulia M. Polak
8 }; k2 R/ f7 \" {) b2 ]8 QSection 2 Finance
# A' a+ J" |0 g3 WChapter 2 A New Political–Financial Paradigm for Medical Research:' s9 S# {+ S _: R r8 W
The California Model?........................................................................ 119 m3 S. C2 H3 v1 m1 a$ g
Robert N. Klein and Alan Trounson" Y$ ~1 V% W' g; s: i' I( G
Chapter 3 Investment Models: Public Funding in Australia................................ 35. o. P a1 ?+ F/ w
Graham Macdonald1 G# c, m5 @4 n' y
Chapter 4 Canada: Capitalizing on a 50-Year Legacy......................................... 43
9 W. K. M. n3 @5 t5 \1 [Andrew Lyall
% [. Y# }2 i. _" {# Q1 W0 kChapter 5 Investing in Regenerative Medicine: What Drives Private Investors?.... 599 J W3 j7 ?/ e. j$ _! i1 k
Catherine D. Prescott
/ R0 U8 W$ H2 l3 H4 w/ N0 KChapter 6 Public Investment Models: Coming out of the Closet and
6 D' j& I& M! E0 U2 SGoing Public!...................................................................................... 67: C Y; N3 z- X6 b3 q8 }
Reni Benjamin
; } O3 r4 w! ]( c0 r- ]Section 3 Business Models
7 t, X" A: a; y) Q% o' kChapter 7 Cell-Based Products: Allogeneic.........................................................855 Z+ z! J& W+ i& k, k" P. J
Paul Kemp
# Y/ m$ F8 w. a: h- a- e9 gChapter 8 Autologous Cell-Based Products: Fulfilling the Promise of
) a+ X# D* h( MCell Therapy........................................................................................97# [1 p, p z+ { N
Eduardo Bravo and Magdalena Blanco-Molina
8 S0 ^0 w. U4 t* f3 h" U; K1 b' ?Chapter 9 Business Models for Cord Blood....................................................... 117
C; [7 N/ c2 @Suzanne M. Watt
: ^/ `9 w% d+ JChapter 10 Changing the Game of Drug Discovery............................................ 131# b9 F, I! s) X6 u
John Walker9 K2 q5 W _# r: w0 a( v4 ], {, `& ~
Chapter 11 Discovery of Small Molecule Regenerative Drugs........................... 141
; ]. m1 _, H+ Z( \Yen Choo! o8 m0 Y5 l6 `% I3 }8 v' p3 m( F
Chapter 12 Adoption of Therapeutic Stem Cell Technologies by Large
" A7 `: |/ l; ?& x* zPharmaceutical Companies............................................................... 153, R0 l; u, c) y5 n4 {" T& Z$ ~% b
Alain A. Vertès+ J9 A7 t# I0 q* [
Chapter 13 Role of Tool and Technology Companies in Successful
v2 N" ^0 }# v, RCommercialization of Regenerative Medicine.................................. 177
0 h4 C1 y3 L4 x* L% w0 dJoydeep Goswami and Paul Pickering
- y2 z3 W& |" m7 b1 B5 kChapter 14 Key Considerations in Manufacturing of Cellular Therapies........... 189, `+ I' Z I1 } }' L5 ?0 y0 u1 x
Robert A. Preti- G9 s) f4 q% a, C1 o# g
Chapter 15 State of the Global Regenerative Medicine Industry........................ 213
, `! I! z6 |1 {% |R. Lee Buckler, Robert Margolin, and Sarah A. Haecker
' U8 W% _3 v$ X0 pSection 4 Intellectual Property5 P6 J1 d- r v. @$ {
Chapter 16 Regenerating Intellectual Property: Europe after WARF................. 2393 t4 ]/ w% W/ a" f1 F
Julian Hitchcock and Devanand Crease
. f Q6 J) A0 i. V/ tChapter 17 Protecting Regenerative Medicine Intellectual Property in the
7 x7 T$ Y9 x6 M8 r* BUnited States: Problems and Strategies............................................. 257
% i: T0 o( f9 h! ^David Resnick, Ronald I. Eisenstein, and Joseph M. McWilliams
2 A# b" V2 E, ~: `& v. K* a/ yChapter 18 Impacts of Indian Policies and Laws on Regenerative7 N1 K6 N: U0 u1 }
Medicine Patent Applications........................................................... 2817 u9 X) R/ \) J5 W, _& B3 A- T
Prabuddha Ganguli
2 G9 v) |& S3 e5 LSection 5 Regulatory Landscape0 v9 Z$ @& p" N1 E
Chapter 19 A CATalyst for Change: Regulating Regenerative Medicines in
% E8 T( P8 r/ x" l0 lEurope...............................................................................................295
+ o- a3 [# G$ M+ _! zChristopher A. Bravery
6 w! [7 J7 p" d `Chapter 20 United States Regulatory Reimbursement, Political
- y' E1 f3 e7 K9 NEnvironment, and Strategies for Reform........................................... 323* P' r% e5 ^0 L- y0 J
Michael J. Werner. S# r& K0 r/ g
Section 6 Reimbursement4 W, k2 g' x6 w. @! O. Z- B1 N
Chapter 21 The Fourth Hurdle: Reimbursement Strategies for
9 z1 t# u( w9 h& JRegenerative Medicine in Europe..................................................... 337
8 k* o( ^8 e) cFrançois M. Meurgey and Micheline Wille7 J7 S* I& P8 o
Chapter 22 Cellular Therapies and Regenerative Medicine: Preparing for
7 e: y* S/ T6 ~$ a+ g1 vReimbursement in the United States................................................. 3519 S% E: I! ^$ n/ w
Eric Faulkner, K* A- T$ d$ C% `8 ~9 v1 d
Chapter 23 Adoption and Evaluation of Regenerative Medicine and the
2 U" J' s0 _+ [) [* zNational Health Service....................................................................369
/ U% c/ D# Q! {# |4 {4 JMargaret Parton
4 i+ q2 V% B6 A' d: ESection 7 I nsurance and Risk Management4 s4 r1 e+ h0 F5 o
Chapter 24 Role of Insurance: If You Build It, Will They Insure It?.................. 379, G2 O* O6 T8 X* T+ R
Matthew Clark
, f/ Q( C8 P" Z- ~* ]& wIndex....................................................................................................................... 391
0 E7 t/ s4 @4 [# c6 R3 o5 Q* I+ q" U' N0 ]) F" B; N
[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 包包 + 10
查看全部评分
|
发表于 2013-5-5 09:27
